文献速递胸部肿瘤头颈与中枢神经肿瘤

EGFR与ALK驱动非小细胞肺癌脑转移患者使用酪氨酸激酶抑制剂联合或不联合 upfront 立体定向放射外科治疗(TURBO-NSCLC)

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
PubMed 文献 · J Clin Oncol · 2024-07-24

该多中心回顾性研究纳入317例EGFR或ALK驱动非小细胞肺癌脑转移患者,比较CNS穿透性TKI联合或不联合upfront SRS的疗效。结果显示联合SRS显著改善至CNS进展时间和局部CNS控制,但总生存无差异;直径≥1 cm的脑转移患者可能获益最大。

要点

  • TKI联合upfront SRS较单用TKI显著改善至CNS进展时间(HR 0.63)。
  • 联合SRS显著改善局部CNS控制(HR 0.30),但远处CNS控制无显著差异。
  • 两组中位OS相似(41个月 vs 40个月),直径≥1 cm脑转移患者可能从upfront SRS获益最大。

核心结论

  • 在EGFR和ALK驱动NSCLC脑转移患者中,在CNS穿透性TKI基础上加用upfront SRS改善了至CNS进展时间和局部CNS控制,但未改善OS。
  • 直径≥1 cm的脑转移患者可能从upfront SRS中获益最大。

研究设计与样本

  • 回顾性收集美国七家学术中心2013年至2022年期间接受CNS穿透性TKI治疗(联合或不联合upfront SRS)的初治TKI的EGFR和ALK驱动NSCLC脑转移患者数据。
  • 共纳入317例患者,其中TKI单药组200例,TKI联合SRS组117例。
  • 采用Fine & Gray和Cox比例风险模型进行多变量校正分析。

主要发现

  • 250例(79%)接受奥希替尼,61例(19%)接受阿来替尼。
  • TKI联合SRS组患者更可能有脑转移灶≥1 cm(P < .001)和神经系统症状(P < .001)。
  • TKI组与TKI联合SRS组的中位OS相似(分别为41个月 vs 40个月;P = .5)。
  • 多变量分析显示,TKI联合SRS与至CNS进展时间显著改善相关(HR 0.63 [95% CI, 0.42 to 0.96];P = .033)。
  • TKI联合SRS显著改善局部CNS控制(HR 0.30 [95% CI, 0.16 to 0.55];P < .001),而远处CNS控制无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Newer-generation tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited. MATERIALS AND METHODS: Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States. Time-to-CNS progression and overall survival (OS) were analyzed, with multivariable adjustment in Fine & Gray and Cox proportional hazards models for clinically relevant factors. RESULTS: From 2013 to 2022, 317 patients were identified (200 TKI-only and 117 TKI + SRS). Two hundred fifty (79%) and 61 (19%) patients received osimertinib and alectinib, respectively. Patients receiving TKI + SRS were more likely to have BM ≥1 cm (P < .001) and neurologic symptoms (P < .001) at presentation. Median OS was similar between the TKI and TKI + SRS groups (median 41 v 40 months, respectively; P = .5). On multivariable analysis, TKI + SRS was associated with a significant improvement in time-to-CNS progression (hazard ratio [HR], 0.63 [95% CI, 0.42 to 0.96]; P = .033). Local CNS control was significantly improved with TKI + SRS (HR, 0.30 [95% CI, 0.16 to 0.55]; P < .001), whereas no significant differences were observed in distant CNS control. Subgroup analyses demonstrated a greater benefit from TKI + SRS in patients with BM ≥1 cm in diameter for time-to-CNS progression and CNS progression-free survival. CONCLUSION: The addition of up-front SRS to CNS-penetrant TKI improved time-to-CNS progression and local CNS control, but not OS, in patients with BM from EGFR- and ALK-driven NSCLC. Patients with larger BM (≥1 cm) may benefit the most from up-front SRS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pike LRG, Miao E, Boe LA, et al. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024. PMID: 39047224. doi:10.1200/JCO.23.02668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。